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Abstract
Objective—To describe the clinical management of menorrhagia in a woman with
Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT).
Design—Case report.
Setting—Large translation research hospital.
Patient—A 26 year old nulligravid woman with familial HPT-JT presented with life-long
menorrhagia resistant to progesterone IUD therapy and a desire for fertility.
Intervention—Aromatase inhibitor therapy.
Main Outcome Measures—Clinical response to therapy and pregnancy.
Result—Imaging demonstrated an enlarged endometrial lining and thickening of the junctional
zone. At operative hysteroscopy, multiple atypical endometrial polyp-like lesions filled the entire
uterine cavity and were removed. Histologic evaluation demonstrated the lesions to be
adenomyomas with an abundance of aromatase expression. Postoperative treatment included an
aromatase inhibitor. The patient's menorrhagia, which had previously been resistant to
progesterone IUD therapy, resolved with the aromatase inhibitor. After ten months of this
treatment, the aromatase inhibitor was discontinued and a repeat hysteroscopy revealed a
markedly improved uterine cavity. The patient subsequently became pregnant on her first natural
cycle and delivered a healthy term infant.
Conclusion—Aromatase inhibitors may represent a novel treatment for benign uterine
pathology in HPT-JT.
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Introduction
The Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT) is a rare autosomal dominant
syndrome resulting from loss-of-function mutation in the gene CDC73/HRPT2 (1). The
product of the gene is parafibromin, a ubiquitously expressed protein and a putative tumor
suppressor (2, 3). Parafibromin has both nuclear and nucleolar localization signals and the
L95P missense mutation described in our case study causes loss of nucleolar localization
which may result in dominant interference causing enhanced cell cycle progression and
increased cell survival (4). Germline mutations in CDC73/HRPT2 resulting in loss of
parafibromin function predispose patients to fibro-osseous jaw tumors and parathyroid
tumors (2). Recently, it was noted that females with this disorder have decreased
reproductive potential and a high prevalence of atypical uterine tumors (3) In addition,
affected women experience profound abnormal uterine bleeding, which often results in
hysterectomy in their thirties due to life threatening menorrhagia (3).
Case
A 26 year old nulligravida woman from a family with HPT-JT was referred for life-long
menorrhagia resulting in anemia. Members of her family were known to carry a L95P
missense mutation in CDC73/HRPT2 (4), and several were affected with HPT-JT, including
the patient's brother who had severe comorbidities from hyperparathyroidism. The patient
had a medical history of hypertension since the age of ten, subclinical hypothyroidism, and
hyperprolactinemia from a microprolactinoma. She had previous treatment of her
microprolactinoma with cabergoline, which was subsequently discontinued. At presentation
to our clinic, she was not on medication for hyperprolactinemia, had normal prolactin levels
and a stable 3mm pituitary adenoma on MRI imaging. Biochemical screening showed no
evidence of hypercalcemia or hyperparathyroidism. She had prior surgical removal of a
large, benign polyp prolapsing through the cervix. The patient desired management of her
menorrhagia and the ability to conceive. She had a progesterone intrauterine device in the
uterus on presentation. She was seen under an institutional review board approved research
protocol at the National Institutes of Health and signed written, informed consent. The
patient was genotyped and found to be heterozygous for a germline L95P parafibromin
missense mutation.
Materials and Methods
Transvaginal ultrasonography was performed with a Voluson E6 (General Electric,Fairfield,
CT). Surgical specimens obtained at hysteroscopic resection were fixed and paraffin
embedded. Serial sections were reacted with Anti-Aromatase antibody (Abcam ab35604).
Staining for aromatase was performed in a control endometrial biopsy and endometrial
tissue from the case patient resected at surgery.
Results
Physical examination was notable for a large everted external cervical os. Transvaginal
ultrasound and magnetic resonance imaging demonstrated an enlarged endometrial lining
with thickening of the junctional zone (Figure 1). The cervix had multiple cystic structures
and was enlarged to the size of the uterine corpus. Operative hysteroscopy revealed a uterine
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cavity filled with atypical, fibrous endometrial polyp-like structures which extended from
the fundus and down through the cervix (Figure 2). The largest lesion was 15mm. The
polyps were surgically removed with electrocautery and multiple mucous filled cysts were
seen which extruded “chocolate like” material on cauterization. Due to the extensive nature
of the polypoid structures, not all of them could be removed and sharp curettage was
performed. Histologic examination of these polypoid structures revealed benign uterine
adenomyomas. A new progesterone IUD was placed in the uterine cavity in the operating
room for management of menorrhagia.
Five months later the patient presented with persistence of menorrhagia. Special staining for
aromatase was then performed on her histologic tissue samples from the prior surgery. This
staining revealed an over-expression of aromatase within her adenomyomas as compared to
normal controls without adenomyomas (Figure 3). The patient was started on an aromatase
inhibitor (Letrozole 2.5 mg/day). The patient received transvaginal ultrasound monitoring
every three months. At each monitoring appointment the ovaries were normal in appearance
without the formation of cystic structures. Upon follow up six months after the aromatase
inhibitor was started, the patient noted decreased uterine bleeding and her endometrial lining
was thin at 4mm.
Post-operatively, the patient received medical therapy with an aromatase inhibitor and a
progesterone intrauterine device. This treatment was continued for a total of ten months
resulting in continued improvement in her symptoms. The patient desired pregnancy and a
follow-up hysteroscopy documented dramatic improvement in the uterine cavity with a few
smaller polyps the largest of which was 3mm. The IUD and the remaining small polyps
were surgically removed. The aromatase inhibitor was discontinued three months after
surgery and the patient became spontaneously pregnant with her next ovulatory cycle. She
had an uncomplicated pregnancy resulting in a term spontaneous vaginal delivery of a
4479gm female.
Discussion
Parathyroid tumors resulting in hyperparathyroidism are the typical presenting manifestation
and occur in some 90% of patients with HPT-JT (5). Ossifying jaw tumors occur in ~35% of
patients and less prevalent features include renal tumors and cysts (3). Only recently it has
been recognized that this syndrome is also associated with a spectrum of uterine disease.
This was first described in a report of two sisters who with HPT-JT who both had uterine
adenomyomatous polyps similar to those describe in this case report (6). In the largest case
series of women with HPT-JT, 31 of 39 women from 13 families had menorrhagia leading
to hysterectomy at a mean age of thirty-five years (3). Of patients in whom histologic
specimens were available for review, there were eight cases of extensive adenomyosis, five
adenofibromas, four leiomyomas, four endometrial hyperplasia, and two adenosarcomas (3).
The tumors were noted to derive from a common embryologic origin of mesodermal
Mullerian tissue. Females with HPT-JT were more likely to be childless as compared to their
unaffected female siblings (27% versus 3%, p<0.001) (3). Furthermore, affected females
were significantly more likely to be childless as compared to their affect male siblings (27%
versus 4%), suggesting the increased childlessness is these affected families occurred in
females but not males (3). Subsequent case series have confirmed the association of HPT-JT
syndrome and uterine tumors, with uterine pathology occurring in 33-79% of affected
females (7-10). It is unclear whether the decreased offspring seen in affected females is the
direct result of early hysterectomy or related to infertility or miscarriage from the uterine
pathology itself. These observations demonstrate the significant pathology of HPT-JT on the
female reproductive tract and reproductive potential.
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To our knowledge, assessment of aromatase expression in the uterine pathology of HPTJT
has not been reported. Aromatase and 17-hydroxysteroid dehydrogenase have been
demonstrated to be overexpressed in leiomyoma as compared to normal myometrial tissue
(11). This raises a potential mechanism by which local conversion of androgens to estrogens
is involved in the growth of leiomyomas, a mechanism supported by the observation that
hypoestrogenic states are typically associated with a decrease in leiomyoma size (11).
Treatment with aromatase inhibitors has been shown to decrease leiomyoma volume and
increase hematocrit (12,13).
The data showing increased aromatase expression in leiomyomas led us to evaluate the
aromatase expression in the histologic adenomyoma specimens from this patient. Testing for
somatic DNA changes and aberrant protein expression in the uterine tumors of HPT-JT
patients in an important next step in understanding the pathogenesis of these tumors (3). The
finding of increased aromatase expression in this patient's adenomyomas led us to add an
aromatase inhibitor to her medical treatment regimen. While her symptomatology had not
improved after hysteroscopic resection and progesterone IUD therapy, the aromatase
inhibitor therapy resulted in clinical improvement in her menorrhagia. Further, repeat
hysteroscopy revealed a markedly improved uterine cavity with the presence of only a few
small lesions. Finally, the patient was able to immediately become pregnant after
discontinuation of the therapy.
In an endometrial explant culture study, it was demonstrated that exposure of endometrial
cells to androgens, specifically androstenedione, resulted in marked up-regulation of
aromatase mRNA (5). The resulting increase in estradiol production induced expression of
SF-1, which led to further activation of CYP19 promotor expression, and increased estradiol
production. These results suggested a positive feed-forward mechanism of androgen to
estradiol production resulting in increased survival and proliferation of endometrial cells.
Aromatase inhibitors were shown to suppress the stimulatory effects of androstenedione,
testosterone, and estradiol on aromatase mRNA (5). Disruption of this feed-forward loop
may be beneficial decreasing local estradiol production and in disrupting the pathogenesis of
endometrial diseases. In addition, blocking aromatization to estradiol would be expected to
lead to an increase in local androgen levels, which may inhibit local cell growth and
endometrial secretory activity (6). Aromatase inhibitors have also been show to decrease the
expression of IGF-1, prostaglandin E, and vascular endothelia growth factor in both
endometrial explants and myometrium, providing additional potential mechanisms by which
local growth factors can be inhibited with aromatase inhibitor treatment (7).
Further study is needed to characterize the uterine tumors found in women with HPT-JT. In
this case report, the use of aromatase inhibitors resulted in marked clinical improvement,
decreased menorrhagia, and the ability to conceive. This may represent a novel therapy for
the medical therapy of benign uterine lesions in women with HPT-JT.
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Aromatase inhibitor therapy improved progesterone resistant menorrhagia in a patient
with Hyperparathyroidism-Jaw Tumor Syndrome.
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Transvaginal ultrasound of the uterus (sagittal view) demonstrating a thickened endometrial
lining (red arrow), increased junctional zone, and enlarge cervix (blue arrow) with multiple
cystic structures.
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Hysteroscopic view of the uterine cavity. Left (A) and Right (B) views revealed multiple
adenomyomas measuring up to 15mm in size. Biopsy confirmed adenomyomas.
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Surgical specimens were fixed and paraffin embedded. Serial sections were reacted with
Anti-Aromatase antibody (Abcam ab35604). Staining for aromatase in a control endometrial
biopsy (left) and an endometrial adenomyoma resected at surgery (right). The right panel
shows increased staining for aromatase in the mesodermal and glandular HPT-JT tissue.
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